Published in PLoS One on April 28, 2011
PrP(ST), a soluble, protease resistant and truncated PrP form features in the pathogenesis of a genetic prion disease. PLoS One (2013) 1.45
Structural plasticity of the cellular prion protein and implications in health and disease. Proc Natl Acad Sci U S A (2013) 0.85
Nanopore analysis of wild-type and mutant prion protein (PrP(C)): single molecule discrimination and PrP(C) kinetics. PLoS One (2013) 0.85
Requirements for mutant and wild-type prion protein misfolding in vitro. Biochemistry (2015) 0.85
A novel mutation I215V in the PRNP gene associated with Creutzfeldt-Jakob and Alzheimer's diseases in three patients with divergent clinical phenotypes. J Neurol (2012) 0.83
Molecular dynamics analysis of apolipoprotein-D-lipid hydroperoxide interactions: mechanism for selective oxidation of Met-93. PLoS One (2012) 0.82
Structural and dynamic properties of the human prion protein. Biophys J (2014) 0.82
Integrity of helix 2-helix 3 domain of the PrP protein is not mandatory for prion replication. J Biol Chem (2012) 0.82
Decrypting Prion Protein Conversion into a β-Rich Conformer by Molecular Dynamics. J Chem Theory Comput (2013) 0.78
Disruption of the X-loop turn of the prion protein linked to scrapie resistance. Protein Eng Des Sel (2012) 0.78
Failure of prion protein oxidative folding guides the formation of toxic transmembrane forms. J Biol Chem (2012) 0.78
The landscape of the prion protein's structural response to mutation revealed by principal component analysis of multiple NMR ensembles. PLoS Comput Biol (2012) 0.77
DNA Polymerase Conformational Dynamics and the Role of Fidelity-Conferring Residues: Insights from Computational Simulations. Front Mol Biosci (2016) 0.75
Complex folding and misfolding effects of deer-specific amino acid substitutions in the β2-α2 loop of murine prion protein. Sci Rep (2015) 0.75
The role of Cys179-Cys214 disulfide bond in the stability and folding of prion protein: insights from molecular dynamics simulations. J Mol Model (2014) 0.75
Early structural features in mammalian prion conformation conversion. Prion (2012) 0.75
WHAT IF: a molecular modeling and drug design program. J Mol Graph (1990) 24.35
Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A (1993) 10.36
Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature (2007) 10.02
The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol (2009) 7.36
NMR structure of the mouse prion protein domain PrP(121-231). Nature (1996) 6.37
NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A (2000) 4.80
Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med (2001) 4.75
Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature (1997) 4.03
Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci U S A (1997) 3.78
A transmembrane form of the prion protein in neurodegenerative disease. Science (1998) 3.76
Sending signals dynamically. Science (2009) 3.64
Structural clues to prion replication. Science (1994) 3.43
Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol (2010) 3.19
Protein oxidation and aging. Free Radic Res (2006) 2.94
Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 2.78
Prions: protein aggregation and infectious diseases. Physiol Rev (2009) 2.73
Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S A (1992) 2.64
Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure. Proc Natl Acad Sci U S A (2007) 2.55
De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc Natl Acad Sci U S A (2008) 2.10
Prion protein NMR structures of elk and of mouse/elk hybrids. Proc Natl Acad Sci U S A (2005) 2.01
Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry (1999) 1.93
The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One (2008) 1.70
The α-helical C-terminal domain of full-length recombinant PrP converts to an in-register parallel β-sheet structure in PrP fibrils: evidence from solid state nuclear magnetic resonance. Biochemistry (2010) 1.53
The structural biology of protein aggregation diseases: Fundamental questions and some answers. Acc Chem Res (2006) 1.47
Familial mutations and the thermodynamic stability of the recombinant human prion protein. J Biol Chem (1998) 1.43
Diversity in prion protein oligomerization pathways results from domain expansion as revealed by hydrogen/deuterium exchange and disulfide linkage. Proc Natl Acad Sci U S A (2007) 1.39
The effect of disease-associated mutations on the folding pathway of human prion protein. J Biol Chem (2004) 1.34
Biochemistry. An ensemble view of allostery. Science (2010) 1.33
Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A (2007) 1.31
Short protein segments can drive a non-fibrillizing protein into the amyloid state. Protein Eng Des Sel (2009) 1.31
Insight into the PrPC-->PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants. Proc Natl Acad Sci U S A (2004) 1.31
Solution structure of the E200K variant of human prion protein. Implications for the mechanism of pathogenesis in familial prion diseases. J Biol Chem (2000) 1.30
Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci U S A (2009) 1.29
NMR structures of three single-residue variants of the human prion protein. Proc Natl Acad Sci U S A (2000) 1.28
Selective processing and metabolism of disease-causing mutant prion proteins. PLoS Pathog (2009) 1.22
Design of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein. Proc Natl Acad Sci U S A (2009) 1.10
The oligomerization properties of prion protein are restricted to the H2H3 domain. FASEB J (2010) 1.08
Ovine prion protein variant A(136)R(154)L(168)Q(171) increases resistance to experimental challenge with bovine spongiform encephalopathy agent. J Gen Virol (2006) 1.08
Pathogenic mutations in the hydrophobic core of the human prion protein can promote structural instability and misfolding. J Mol Biol (2010) 1.08
Disease-associated F198S mutation increases the propensity of the recombinant prion protein for conformational conversion to scrapie-like form. J Biol Chem (2002) 1.08
Prion proteins with different conformations accumulate in Gerstmann-Sträussler-Scheinker disease caused by A117V and F198S mutations. Am J Pathol (2001) 1.07
Oxidation of Helix-3 methionines precedes the formation of PK resistant PrP. PLoS Pathog (2010) 1.06
Prion protein NMR structure from tammar wallaby (Macropus eugenii) shows that the beta2-alpha2 loop is modulated by long-range sequence effects. J Mol Biol (2009) 1.06
Methionine sulfoxides on PrPSc: a prion-specific covalent signature. Biochemistry (2008) 1.03
Methionine sulfoxides on prion protein Helix-3 switch on the alpha-fold destabilization required for conversion. PLoS One (2009) 1.01
Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J Biol Chem (2001) 1.01
Prion fibrillization is mediated by a native structural element that comprises helices H2 and H3. J Biol Chem (2010) 1.00
Structural facets of disease-linked human prion protein mutants: a molecular dynamic study. Proteins (2010) 0.97
Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathol (2005) 0.95
Predicting interaction sites from the energetics of isolated proteins: a new approach to epitope mapping. Biophys J (2010) 0.95
The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci (2010) 0.95
Aggresome formation by mutant prion proteins: the unfolding role of proteasomes in familial prion disorders. J Alzheimers Dis (2003) 0.94
Pharmacological chaperone for the structured domain of human prion protein. Proc Natl Acad Sci U S A (2010) 0.90
Structural instability of the prion protein upon M205S/R mutations revealed by molecular dynamics simulations. Biophys J (2006) 0.88
Diverse effects on the native β-sheet of the human prion protein due to disease-associated mutations. Biochemistry (2010) 0.84
Regulating the conformation of prion protein through ligand binding. J Phys Chem B (2009) 0.82
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell (2010) 2.24
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest (2009) 1.72
Mechanism by which 2,2,2-trifluoroethanol/water mixtures stabilize secondary-structure formation in peptides: a molecular dynamics study. Proc Natl Acad Sci U S A (2002) 1.64
Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology. Chem Biol (2013) 1.45
Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer. PLoS Comput Biol (2009) 1.43
Detection of oxidized methionine in selected proteins, cellular extracts and blood serums by novel anti-methionine sulfoxide antibodies. Arch Biochem Biophys (2009) 1.29
Study of the Villin headpiece folding dynamics by combining coarse-grained Monte Carlo evolution and all-atom molecular dynamics. Proteins (2005) 1.18
PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. J Biol Chem (2005) 1.17
Beta-hairpin conformation of fibrillogenic peptides: structure and alpha-beta transition mechanism revealed by molecular dynamics simulations. Proteins (2004) 1.09
Molecular simulation of multistate peptide dynamics: a comparison between microsecond timescale sampling and multiple shorter trajectories. J Comput Chem (2008) 1.07
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst (2006) 1.06
Sequence dependence of amyloid fibril formation: insights from molecular dynamics simulations. J Mol Biol (2005) 1.04
Methionine sulfoxides on PrPSc: a prion-specific covalent signature. Biochemistry (2008) 1.03
Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem (2006) 1.03
Corresponding functional dynamics across the Hsp90 Chaperone family: insights from a multiscale analysis of MD simulations. PLoS Comput Biol (2012) 1.01
Understanding the determinants of stability and folding of small globular proteins from their energetics. Protein Sci (2004) 1.00
Effect of hexafluoroisopropanol alcohol on the structure of melittin: a molecular dynamics simulation study. Protein Sci (2005) 0.97
Molecular mechanism of allosteric communication in Hsp70 revealed by molecular dynamics simulations. PLoS Comput Biol (2012) 0.97
Relationship between energy distribution and fold stability: Insights from molecular dynamics simulations of native and mutant proteins. Proteins (2008) 0.96
Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget (2010) 0.96
Investigating the mechanism of peptide aggregation: insights from mixed monte carlo-molecular dynamics simulations. Biophys J (2008) 0.95
Predicting interaction sites from the energetics of isolated proteins: a new approach to epitope mapping. Biophys J (2010) 0.95
The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci (2010) 0.95
Exploiting antigenic diversity for vaccine design: the chlamydia ArtJ paradigm. J Biol Chem (2010) 0.94
Misfolding of the amyloid beta-protein: a molecular dynamics study. Proteins (2006) 0.94
Molecular recognition and drug-lead identification: what can molecular simulations tell us? Curr Med Chem (2010) 0.91
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol (2005) 0.90
A multiscale approach to characterize the early aggregation steps of the amyloid-forming peptide GNNQQNY from the yeast prion sup-35. PLoS Comput Biol (2011) 0.89
Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide. Chemistry (2008) 0.89
Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther (2012) 0.89
A decoy set for the thermostable subdomain from chicken villin headpiece, comparison of different free energy estimators. BMC Bioinformatics (2005) 0.88
Role of an intrasubunit disulfide in the association state of the cytosolic homo-oligomer methionine adenosyltransferase. J Biol Chem (2002) 0.88
Determinants of protein stability and folding: comparative analysis of beta-lactoglobulins and liver basic fatty acid binding protein. Proteins (2005) 0.87
Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry (2002) 0.87
Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides. Chemistry (2003) 0.87
Modeling the alpha-helix to beta-hairpin transition mechanism and the formation of oligomeric aggregates of the fibrillogenic peptide Abeta(12-28): insights from all-atom molecular dynamics simulations. J Mol Graph Model (2004) 0.86
3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. ACS Med Chem Lett (2012) 0.86
Molecular dynamics simulations of proteins and peptides: from folding to drug design. Curr Protein Pept Sci (2008) 0.86
Rational epitope design for protein targeting. ACS Chem Biol (2012) 0.85
A structure-based strategy for epitope discovery in Burkholderia pseudomallei OppA antigen. Structure (2012) 0.84
Mechanism of helix nucleation and propagation: microscopic view from microsecond time scale MD simulations. J Phys Chem B (2005) 0.83
Computational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors. Biochemistry (2010) 0.83
Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS One (2012) 0.82
Deforestation and the structure of frog communities in the Humedale Terraba-Sierpe, Costa Rica. Zoolog Sci (2009) 0.81
Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. J Chem Inf Model (2014) 0.81
Selecting sequences that fold into a defined 3D structure: A new approach for protein design based on molecular dynamics and energetics. Biophys Chem (2009) 0.81
Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem (2009) 0.81
Updated management of non-st-segment elevation acute coronary syndromes: selection of patients for low-cost care: an analysis of outcome and cost effectiveness. Med Sci Monit (2005) 0.81
Energetic and dynamic aspects of the affinity maturation process: characterizing improved variants from the bevacizumab antibody with molecular simulations. J Chem Inf Model (2013) 0.81
Identification of domains in protein structures from the analysis of intramolecular interactions. J Phys Chem B (2012) 0.81
Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens. J Virol (2008) 0.80
Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design. Curr Top Med Chem (2009) 0.80
Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols. ChemMedChem (2007) 0.80
A molecular dynamics study of the interaction of D-peptide amyloid inhibitors with their target sequence reveals a potential inhibitory pharmacophore conformation. J Mol Biol (2008) 0.80
Inactivation of TEM-1 by avibactam (NXL-104): insights from quantum mechanics/molecular mechanics metadynamics simulations. Biochemistry (2014) 0.80
Investigating dynamic and energetic determinants of protein nucleic acid recognition: analysis of the zinc finger zif268-DNA complexes. BMC Struct Biol (2010) 0.80
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin Ther (2004) 0.80
Why is a protective antigen protective? Hum Vaccin (2009) 0.80
Investigating allostery in molecular recognition: insights from a computational study of multiple antibody-antigen complexes. J Phys Chem B (2013) 0.79
An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem (2009) 0.79
Similar folds with different stabilization mechanisms: the cases of Prion and Doppel proteins. BMC Struct Biol (2006) 0.79
From crystal structure to in silico epitope discovery in the Burkholderia pseudomallei flagellar hook-associated protein FlgK. FEBS J (2015) 0.78
Structure determination and dynamics of peptides overlapping the catalytic hairpin of the Ras-specific GEF Cdc25(Mm). Biochemistry (2003) 0.78
Structural analysis of a helical peptide unfolding pathway. Chemistry (2010) 0.78
Molecular simulations of peptides: a useful tool for the development of new drugs and for the study of molecular recognition. Methods Mol Biol (2009) 0.78
Folding and mis-folding of peptides and proteins: insights from molecular simulations. Mini Rev Med Chem (2005) 0.77
Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease. Expert Rev Pharmacoecon Outcomes Res (2005) 0.77
Atomic force fluorescence microscopy in the characterization of amyloid fibril assembly and oligomeric intermediates. Methods Mol Biol (2012) 0.77
Characterization of the conformational space of a triple-stranded beta-sheet forming peptide with molecular dynamics simulations. Proteins (2004) 0.77
A Hamiltonian replica exchange molecular dynamics (MD) method for the study of folding, based on the analysis of the stabilization determinants of proteins. Int J Mol Sci (2013) 0.76
Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain. Chem Biol Drug Des (2010) 0.76
Structure and sequence determinants of aggregation investigated with molecular dynamics. Front Biosci (Landmark Ed) (2009) 0.76
Biochemical and computational insights into the anti-aromatase activity of natural catechol estrogens. J Steroid Biochem Mol Biol (2008) 0.76
Peptides for immunological purposes: design, strategies and applications. Amino Acids (2013) 0.76
Molecular dynamics simulations of hsp90 with an eye to inhibitor design. Pharmaceuticals (Basel) (2012) 0.75
Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis. Ther Clin Risk Manag (2008) 0.75
Computational approaches elucidate the allosteric mechanism of human aromatase inhibition: a novel possible route to Small-molecule regulation of CYP450s activities? J Chem Inf Model (2014) 0.75
Covalent docking of selected boron-based serine beta-lactamase inhibitors. J Comput Aided Mol Des (2015) 0.75
HMGB1-carbenoxolone interactions: dynamics insights from combined nuclear magnetic resonance and molecular dynamics. Chem Asian J (2011) 0.75
Enzymatic and Inhibition Mechanism of Human Aromatase (CYP19A1) Enzyme. A Computational Perspective from QM/MM and Classical Molecular Dynamics Simulations. Mini Rev Med Chem (2016) 0.75
The molecular dynamics of assembly of the ubiquitous aortic medial amyloidal medin fragment. J Mol Graph Model (2006) 0.75
Role of THz Fluctuations in the Allosteric Properties of the PDZ Domains. J Phys Chem B (2017) 0.75
Screening Complex Biological Samples with Peptide Microarrays: The Favorable Impact of Probe Orientation via Chemoselective Immobilization Strategies on Clickable Polymeric Coatings. Bioconjug Chem (2016) 0.75